Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Glucose→

Glucose Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
50-99-7
Molecular formula
C6H12O6
Molecular weight
180.16 g/mol
Drug class
Monosaccharide carbohydratemetabolic substrate and intravenous energy/electrolyte vehicle
Mechanism of action
Enters glycolysis and oxidative phosphorylation to produce ATP. Intravenous glucose raises blood glucose and provides substrate for cellular energy metabolism; in hyperinsulinaemic states it counteracts hypoglycaemia.
Indications / reported uses
  • Treatment of hypoglycaemia using oral or intravenous glucose, with concentration and route chosen according to severity and clinical setting
  • Intravenous glucose solutions provide fluid and carbohydrate calories and may be used in perioperative or parenteral nutrition settings; these are formulation-specific uses

Sources: NHS — Low blood sugar (hypoglycaemia) treatment · NLM MeSH — Glucose · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Monosaccharide carbohydrate; metabolic substrate and intravenous energy/electrolyte vehicle

Mechanism of action

Enters glycolysis and oxidative phosphorylation to produce ATP. Intravenous glucose raises blood glucose and provides substrate for cellular energy metabolism; in hyperinsulinaemic states it counteracts hypoglycaemia.

General use cases

  • Treatment of hypoglycaemia using oral or intravenous glucose, with concentration and route chosen according to severity and clinical setting
  • Intravenous glucose solutions provide fluid and carbohydrate calories and may be used in perioperative or parenteral nutrition settings; these are formulation-specific uses

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Glucose Environmental Risk Assessment (ERA) (the Glucose ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.